ADPT
Adaptive Biotechnologies Corporation Common StockData: 2026-09-11
Quick Stats
Sep 11, 202654.7
AI Score
HOLD0.59
Volume Ratio
Nov 04, 2026
Next Earnings
14
+ve Days (30d)
16
-ve Days (30d)
ADPT Price vs Max Options Open Interest
How to read this: the line is the stock price; the bars show where the most option open interest sits each day. Strikes with heavy open interest often act as magnets or barriers for price ("max pain" zones). Scroll right for the most recent days.
ADPT Max Change In Options Open Interest
How to read this: each bar is the option contract whose open interest changed the most yesterday. Green bars = new positions being opened (conviction building at that strike); red bars = positions being closed. Call builds above the current price suggest upside bets; put builds below it suggest hedging or downside bets.
ADPT Options - Sort by Max open Interest (near term)
11th September 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
ADPT Daily Out of Money Options - Sort by Max open Interest (near term)
11th September 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
ADPT Daily In the Money Options - Sort by Max open Interest (near term)
11th September 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | OI | Change in OI |
Volume | Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
ADPT Most Active Options by Volume(near term)
11th September 2026 (Data is delayed in normal mkt. hours)
| Type | Expiration | Strike | Volume | OI | Change in OI |
Ask | PC | Delta | Vega | Volatility | % change | Track |
|---|
ADPT Technical Chart
- Candlesticks: Green = price up, Red = price down. Body shows open/close, wicks show high/low.
- SMAs: Moving averages help identify trends. Price above SMA = bullish, below = bearish.
- Options OI: Shows max open interest strikes. High OI = significant price levels.
- Volume Profile: Shows price levels with most trading activity. POC = Point of Control (highest volume).
- Earnings: Vertical lines mark earnings dates. Watch for volatility around these dates.
- Gamma Walls: Key support/resistance from options gamma exposure. Orange = resistance above, Purple = support below.
- Fibonacci Retracement: Auto-calculated support/resistance levels based on recent high/low. Key levels: 23.6%, 38.2%, 50%, 61.8%, 78.6%.
- Unusual Activity: Highlights days with abnormal volume (2x+ average) or large price moves (5%+). Red marker = unusual activity detected.
Technical Indicators
Volume Profile Analysis
Horizontal histogram showing volume distribution at each price level with buying/selling pressure
ADPT Stock Summary
Last updated Sep 11, 2026
ADPT is currently trading at $24.2, positioned above its 200-day moving average of $17.85, indicating a long-term uptrend. The stock has a 52-week range of $12 to $26.87.
Technical Analysis: The 50-day moving average stands at $23.68, which is below the current price, signaling bullish near-term momentum. The RSI (Relative Strength Index) reads 47.419, suggesting the stock is neutral with balanced momentum.
Money Flow Indicators: The Chaikin Money Flow (20-day) is 0.056, which is positive, indicating accumulation by institutional investors. Our AI-powered investment score rates ADPT at 54.7/100 with a HOLD recommendation.
ADPT (Adaptive Biotechnologies Corporation Common Stock) Indicators
Last updated Sep 11, 2026
| Indicator | Value |
|---|---|
| RSI(14) | 47.419 |
| CMF (20) | 0.056 |
| ROC (10) | -8.472 |
| ADX (14) | 21.498 |
| Indicator | Value |
|---|---|
| MACD (12,26,9) | 0.157 |
| AROONOSC (14) | -64.286 |
| WILLAMS %R (14) | -79.94 |
| MFI (14) | 40.563 |
ADPT Candlestick Patterns
Validated patterns fired in the last 10 sessions. Hit rate = how often price moved in the signal's direction within 5 trading days (backtest: 2.7M signals, 3,500 liquid stocks, Feb 2025–Sep 2026). Baseline: a random stock closes higher 5 days later 53% of the time. Click a row to see the candle on the chart.
| Date | Pattern | Signal | 5-Day Hit Rate | Edge vs Baseline | Sample |
|---|---|---|---|---|---|
| Aug 28 | Marubozu (bearish) (contrarian — textbook says the opposite) | Bullish | 56.2% | +3.2 pts | 30540 |
These are statistical tilts, not standalone trade setups. Only patterns with a measured edge are shown — roughly 50 of 60 textbook patterns showed no edge and are hidden.
Adaptive Biotechnologies Corporation Common Stock is above both the 50 Day and 200 Day SMA which is considered Bullish.
ADPT Moving Averages Analysis
Adaptive Biotechnologies Corporation Common Stock has been above 50 day sma 1 times in last 30 days. Last time it was above 50 day sma was on Sep 11, 2026
Adaptive Biotechnologies Corporation Common Stock has been above 200 day sma 1 times in last 30 days. Last time it was above 200 day sma was on Sep 11, 2026
ADPT (Adaptive Biotechnologies Corporation Common Stock) Simple Moving Averages
Moving Averages are last updated Sep 11, 2026
| Days | MA |
|---|---|
| 10 | 24.51 |
| 20 | 25.03 |
| 30 | 24.82 |
| 50 | 23.68 |
| 100 | 19.72 |
| 200 | 17.85 |
ADPT Fundamental Analysis
| P/E (Forward) | -- |
| P/E (Trailing) | -- |
| Market Cap ($) | 3.9 billion |
| Earnings/Share ($) | -0.4 |
| Net Profit Margin (%) | -0.2073 |
| Dividend/Share ($) | -- |
| EPS Estimate Current Year ($) | -0.5411 |
| EPS Estimate Next Year ($) | -0.1847 |
| WallStreet Target Price ($) | 25.07 |
| Most Recent Quarter |
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).